44
Participants
Start Date
January 31, 2013
Primary Completion Date
May 31, 2017
Study Completion Date
May 31, 2017
Sitagliptin
During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.
Pegvisomant
During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)
Placebo
During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)
L-NMMA
During Aim 2, given during one of two study days (Group A subjects only)
Exendin 9-39
During Aim 2, given during one of two study days (Group C subjects only)
Vanderbilt University Medical Center, Nashville
National Institutes of Health (NIH)
NIH
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Vanderbilt University
OTHER